Artesunate Versus Quinine for Treatment of Severe Falciparum Malaria: A Randomised Trial

By Bruce H. Thiers. 2006

1,015 citations recorded by the source corpus.

Subfields: Pharmacology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/a187c942196110682f2fe28c43d31e45aa913a9e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. J. Roh
2. R. Price
3. Hyejin Jang
4. Eun Hye Kim
5. E. Tjitra
6. P. Sugiarto
7. Daiha Shin
8. Daniel A. Lampah

In Public Health, Environmental and Occupational Health

1. R. Price
2. E. Tjitra
3. P. Sugiarto
4. Daniel A. Lampah
5. E. Kenangalem
6. Noah Warikar
7. M. Karyana
8. N. Anstey

Citations in the corpus

• Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis (2016, background): “Artesunate is a water-soluble semi-synthetic derivative of artemisinin and a first-line treatment for malaria [9].”
• Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria (2011, background): “7% Intravenous artesunate should be treatment of choice for severe malaria in adults [20]”
• Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia (2008, methodology): “In May 2005 protocols for the treatment of severe malaria were revised to intravenous artesunate [14], and in March 2006 the first-line treatment of uncomplicated falciparum and vivax malaria was changed to dihydroartemisinin-piperaquine [15].”